Cargando…

Cancer drug resistance in multiple myeloma

Detalles Bibliográficos
Autor principal:	Uckun, Fatih M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255243/ https://www.ncbi.nlm.nih.gov/pubmed/35800374 http://dx.doi.org/10.20517/cdr.2022.32

Ejemplares similares

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
por: Uckun, Fatih M., et al.
Publicado: (2023)

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma
por: Uckun, Fatih M., et al.
Publicado: (2022)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
por: Uckun, Fatih M., et al.
Publicado: (2018)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Multiple Myeloma: Available Therapies and Causes of Drug Resistance
por: Pinto, Vanessa, et al.
Publicado: (2020)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Chromosomal instability and acquired drug resistance in multiple myeloma
por: Wang, Wang, et al.
Publicado: (2017)

Role of micro-RNAs in drug resistance of multiple myeloma
por: Abdi, Jahangir, et al.
Publicado: (2016)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Methods for reducing delays in the diagnosis of multiple myeloma
por: Koshiaris, Constantinos
Publicado: (2019)

Recent Advances on the Pathobiology and Treatment of Multiple Myeloma
por: Amodio, Nicola
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2018)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug
por: Uckun, Fatih M., et al.
Publicado: (2021)

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
por: Chen, Lucia Y., et al.
Publicado: (2022)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
por: Moscvin, Maria, et al.
Publicado: (2021)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t4inlp889pm5bf3565notbqjjq